Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302) Academic Article uri icon

Overview

MeSH Major

  • Androstenes
  • Antineoplastic Agents, Hormonal
  • Antineoplastic Combined Chemotherapy Protocols
  • Cytochrome P-450 Enzyme Inhibitors
  • Neoplasms, Hormone-Dependent
  • Prostatic Neoplasms, Castration-Resistant
  • Steroid 17-alpha-Hydroxylase

abstract

  • The updated results of this ongoing study showed that disease progression was delayed in patients with advanced prostate cancer who were treated with abiraterone acetate and prednisone, and there was a continued trend in prolongation of life compared with patients treated with prednisone alone. Treatment with abiraterone acetate and prednisone was well tolerated by patients who were treated for >2 yr.

publication date

  • January 2014

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4418928

Digital Object Identifier (DOI)

  • 10.1016/j.eururo.2014.02.056

PubMed ID

  • 24647231

Additional Document Info

start page

  • 815

end page

  • 25

volume

  • 66

number

  • 5